{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.05","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Estimated using Kaplan-Meier analysis.","dispersionType":"Standard Error","groups":[{"description":"Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who fail to achieve at least 25% M-protein reduction for Waldenstrom's macroglobulinemia or partial response for marginal zone lymphoma after 2 courses of carfilzomib will continue to receive carfolzomib for 4 more courses. In addition, they will also receive rituximab IV weekly on days 1, 8, 15, and 22 of course 3 and then monthly on day 1 of courses 4-6 in the absence of disease progression or unacceptable toxicity.\n\nCarfilzomib: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRituximab: Given IV","id":"OG000","title":"Treatment (Carfilzomib, Rituximab)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Time to Progression","type":"SECONDARY","unitOfMeasure":"Months"}